Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


Accelrys Announces Fourth Quarter and Full Year 2012 Results

Accelrys, Inc. (NASDAQ: ACCL) today reported financial results for the fiscal quarter and year ended December 31, 2012, including a 16% year-over-year increase in Non-GAAP revenue in the fourth quarter.

Non-GAAP revenue for the quarter ended December 31, 2012 increased $6.7 million to $47.5 million from $40.8 million for the same quarter of the previous year, or an increase of 16%. Non-GAAP revenue for the year ended December 31, 2012 increased $19.3 million to $174.3 million from $155.0 million for the year ended December 31, 2011, or an increase of 12%.

Non-GAAP net income was $4.5 million, or $0.08 per diluted share, for the quarter ended December 31, 2012 compared to non-GAAP net income of $4.6 million, or $0.08 per diluted share, for the same quarter of the previous year. Non-GAAP net income was $19.6 million, or $0.35 per diluted share, for the year ended December 31, 2012 compared to non-GAAP net income of $19.0 million, or $0.34 per diluted share, for the year ended December 31, 2011.

GAAP revenue for the quarter ended December 31, 2012 increased $4.4 million to $44.2 million from $39.8 million for the same quarter of the previous year, or an increase of 11%. GAAP revenue for the year ended December 31, 2012 increased $18.2 million to $162.5 million from $144.3 million for the year ended December 31, 2011, or an increase of 13%.

GAAP net loss was $(8.2) million, or $(0.15) per diluted share, for the quarter ended December 31, 2012 compared to GAAP net income of $14.2 million, or $0.25 per diluted share, for the same quarter of the previous year. GAAP net loss was $(10.4) million, or $(0.19) per diluted share, for the year ended December 31, 2012 compared to GAAP net income of $1.8 million, or $0.03 per diluted share, for the same period of the previous year.

“We are pleased with our performance in both 2012 and against the three-year plan we developed for our business following our 2010 merger with Symyx. We achieved both market momentum and acknowledgment of our position as the leading provider of scientific innovation lifecycle management software,” said Max Carnecchia, President and CEO. “Performance in the fourth quarter of 2012 was strong as our revenues grew 16% over the prior year. In addition, we completed and are integrating three acquisitions key to our strategy of optimizing the lab-to-market value chain. We remain enthusiastic about the market opportunity in front of us and in our ability to continue to grow orders, revenue and profits both organically and inorganically in 2013.”

Recent Business Highlights:

  • Completed three acquisitions that add important domain expertise and technology capabilities that further our strategy to optimize the innovation lifecycle from research through commercialization.
    • HEOS, a secure Cloud-based information management workspace for scientific collaboration, accelerates and streamlines collaborative drug-discovery.
    • Aegis Analytical Corporation (Aegis), the leading provider of process management informatics software, further expands the footprint in downstream operation with solutions that help aggregate, contextualize and analyze manufacturing, quality and product development data.
    • Vialis AG, a leading systems integrator with deep experience implementing and supporting paperless laboratory solutions, further strengthening Accelrys' position in the laboratory informatics software market.
  • Delivered new product releases in the core product lines and significantly progressed the integration roadmap for the solutions acquired into the portfolio, including:
    • New Accelrys Enterprise Platform (AEP), the industry's first scientifically aware, service-oriented architecture (SOA) that enables integration and deployment of broad scientific solutions (Platform)
    • New biology capabilities from screening through pre-clinical development in the Accelrys Electronic Laboratory Notebook (Enterprise Lab Management)
    • New Process Management and Compliance suite, a unified approach to product development and process management which combines the capabilities of the Accelrys ELN, Accelrys Lab Execution System (LES), Accelrys Electronic Batch Records (EBR) and the Accelrys Enterprise Platform (Enterprise Lab Management)
    • New integration between Accelrys Materials Studio and AEP, enabling computational scientists to collaborate across the enterprise; deepened biotherapeutics capabilities in Accelrys Discovery Studio (Modeling and Simulation)

Non-GAAP results for the quarter and year ended December 31, 2012 exclude the impact of business combination activities associated with the acquisitions of Aegis on October 23, 2012 and Contur Industry Holding AB and Contur Software AB (collectively, “Contur”) and VelQuest Corporation (“VelQuest”), both in 2011, and the merger with Symyx Technologies, Inc. (“Symyx”) in 2010, and other nonrecurring items.

Non-GAAP revenue, non-GAAP operating income, and non-GAAP net income for the quarter and year ended December 31, 2012 include fair value adjustments to deferred revenue ($3.3 million and $11.8 million, respectively). Non-GAAP operating income for such three and twelve-month periods also excludes stock-based compensation expense ($2.5 million and $8.1 million, respectively), business consolidation, transaction and restructuring costs ($6.6 million and $7.8 million, respectively) and purchased intangible asset amortization ($5.2 million and $17.8 million, respectively), offset by an adjustment to include acquisition-related cost of revenue related to VelQuest non-GAAP revenue recognized during such periods ($0.8 million and $1.9 million, respectively). Non-GAAP net income for the quarter and year ended December 31, 2012 also excludes additional purchased intangible asset amortization ($0.4 million and $1.7 million, respectively) offset by removing the impact of the amortization of note receivable discount related to our promissory note receivable from Intermolecular, Inc. (“Intermolecular”) ($0.3 million and $0.9 million, respectively). In addition to the aforementioned items, non-GAAP net income for the year ended December 31, 2012 includes fair value adjustments to deferred royalty income of $0.6 million and excludes $2.1 million in other non-operating income resulting from our real estate related activities.

Calendar Year 2013 Outlook

For the year ending December 31, 2013, the Company expects non-GAAP revenue to be between $185 and $190 million, and non-GAAP diluted earnings per share to be between $0.36 and $0.39 per diluted share on fully diluted weighted average shares outstanding of 56.6 million and using an effective tax rate of 40%.

Non-GAAP Financial Measures:

This press release describes financial measures for revenue, operating income, net income, net income per diluted share and free cash flow that exclude deferred revenue fair value adjustments, acquisition-related cost of revenue, business consolidation, transaction and restructuring costs, stock-based compensation expense, purchased intangible asset amortization, royalty income fair value adjustments, amortization of note receivable discount, gain on sale of real estate, gain on sale of equity investments, sale of intangible assets, other non-operating expense and income tax adjustments. These financial measures are not calculated in accordance with generally accepted accounting principles (GAAP) and are not based on any comprehensive set of accounting rules or principles.

Management believes these non-GAAP financial measures provide a useful measure of the Company's operating results, a meaningful comparison with historical results and with the results of other companies, and insight into the Company's ongoing operating performance. Further, management and the Board of Directors utilize these measures, in addition to GAAP measures, when evaluating and comparing the Company's operating performance against internal financial forecasts and budgets. These non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.

For additional information on the items excluded by the Company from its non-GAAP financial measures please refer to the Form 8-K regarding this release that was furnished today to the Securities and Exchange Commission.

The following table contains a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures (unaudited, amounts in thousands, except per share amounts, including footnotes):

  Three Months Ended   Year Ended
December 31, December 31,
2012   2011 2012   2011
GAAP revenue $ 44,194 $ 39,762 $ 162,526 $ 144,339
Deferred revenue fair value adjustment1 3,332   1,081   11,758   10,652  
Non-GAAP revenue $ 47,526   $ 40,843   $ 174,284   $ 154,991  
 
GAAP operating loss (11,203 ) (2,926 ) (19,054 ) (19,701 )
Deferred revenue fair value adjustment1 3,332 1,081 11,758 10,652
Acquisition-related cost of revenue2 (762 ) (1,921 )
Business consolidation, transaction and restructuring costs3 6,583 1,538 7,845 7,772
Stock-based compensation expense4 2,505 1,424 8,115 5,572
Purchased intangible asset amortization5 5,199   4,638   17,782   18,239  
Non-GAAP operating income $ 5,654 $ 5,755 $ 24,525 $ 22,534
Depreciation expense 872 923 3,325 3,800
Cash received for interest and royalty income 2,002 2,269 9,265 9,574
Cash (paid) for income taxes, net of refunds received (198 ) (153 ) (2,690 ) 1,182
Capital expenditures (3,043 ) (934 ) (6,332 ) (3,908 )
Non-GAAP free cash flow 5,287   7,860   28,093   33,182  
 
GAAP net income (loss) $ (8,229 ) $ 14,205 $ (10,402 ) $ 1,765
Deferred revenue fair value adjustment1 3,332 1,081 11,758 10,652
Acquisition-related cost of revenue2 (762 ) (1,921 )
Business consolidation, transaction and restructuring costs 3 6,583 1,538 7,845 7,772
Stock-based compensation expense4 2,505 1,424 8,115 5,572
Purchased intangible asset amortization5 5,623 5,230 19,477 20,604
Royalty income fair value adjustment6 200 600 803
Amortization of note receivable discount7 (270 ) (932 )
Gain on sale of real estate8 (2,744 )
Gain on sale of equity method investment9 (18,970 ) (18,970 )
Sale of intangible assets10 4,303 4,303
Other non-operating expense11 670
Income tax12 (4,239 ) (4,456 ) (12,855 ) (13,454 )
Non-GAAP net income $ 4,543   $ 4,555   $ 19,611   $ 19,047  
 
GAAP diluted net income (loss) per share $ (0.15 ) $ 0.25 $ (0.19 ) $ 0.03
Deferred revenue fair value adjustment1 0.06 0.02 0.21 0.19
Acquisition-related cost of revenue2 (0.01 ) (0.03 )
Business consolidation, transaction and restructuring costs3 0.12 0.03 0.14 0.14
Stock-based compensation expense4 0.04 0.03 0.14 0.10
Purchased intangible asset amortization5 0.10 0.09 0.34 0.37
Royalty income fair value adjustment6 0.01 0.01
Amortization of note receivable discount7 (0.02 )
Gain on sale of real estate8 (0.05 )
Gain on sale of equity method investment9 (0.34 ) (0.34 )
Sale of intangible assets10 0.08 0.08
Other non-operating expense11 0.01
Income tax12 (0.07 ) (0.08 ) (0.23 ) (0.24 )
Non-GAAP diluted net income per share13 $ 0.08   $ 0.08   $ 0.35   $ 0.34  
Weighted average shares used to compute net income per share:
Basic 55,713 55,587 55,696 55,489
Diluted 56,848 55,933 56,563 56,037

1Deferred revenue fair value adjustment relates to our acquisitions of Aegis, VelQuest and Contur and our merger with Symyx, and adds back the impact of writing down the acquired historical deferred revenue to fair value as required by purchase accounting guidance.

2Acquisition-related cost of revenue relates to our acquisition of VelQuest, and adds back the impact of writing down the acquired deferred cost of revenue as required by purchase accounting guidance.

3Business consolidation, transaction and restructuring costs are included in the business consolidation, transaction and restructuring costs line in our consolidated statements of operations and consist of accounting, legal, litigation and other costs incurred in connection with our acquisition activities, including our merger with Symyx and acquisitions of Contur, VelQuest and Aegis, as well as integration costs incurred in connection with such transactions, including consultant and employee related costs incurred during integration and transition periods. Also included are contingent compensation costs relating to the Contur acquisition as well as lease obligation exit costs, facility closure costs and severance and other related costs incurred in connection with the various restructuring activities commenced by the Company.

4Stock-based compensation expense is included in our consolidated statements of operations as follows:

  Three Months Ended   Year Ended
December 31, December 31,
2012   2011 2012   2011
Cost of revenue $ 262 $ 117 $ 755 $ 333
Product development 517 313 1,763 1,136
Sales and marketing 853 362 2,545 1,672
General and administrative 867 620 3,093 2,428
Business consolidation, transaction and restructuring costs 6   12   (41 ) 3
Total stock-based compensation expense $ 2,505   $ 1,424   $ 8,115   $ 5,572

5Purchased intangible asset amortization is included in our consolidated statements of operations as follows:

  Three Months Ended   Year Ended
December 31, December 31,
2012   2011 2012   2011
Amortization of completed technology $ 2,580 $ 2,135 $ 8,843 $ 8,393
Purchased intangible asset amortization 2,619 2,503 8,939 9,846
Royalty and other income, net 424   592   1,695   2,365
Total purchased intangible amortization expense $ 5,623   $ 5,230   $ 19,477   $ 20,604

6Royalty income fair value adjustment relates to our merger with Symyx, and adds back the impact of writing down deferred royalty income to fair value as required by purchase accounting guidance.

7Amortization of note receivable discount adjusts the amortization of the discount on our promissory note receivable from Intermolecular in connection with the sale of intellectual property in November 2011.

8Gain on sale of real estate relates to the sale of real property, comprised of land and an office building located in Santa Clara, California, which we sold in June 2012. This property was acquired as a result of our merger with Symyx and was not utilized in our ongoing operations.

9Gain on sale of equity investment reflects the gain recognized upon the sale of our investment in Intermolecular in November 2011.

10Sale of intangible asset reflects the write off of our cost basis in the intellectual property sold to Intermolecular in November 2011.

11Other non-operating expense relates to the write off in June 2012 of certain assets in connection with exiting the lease of a restructured facility net of other non-operating income.

12Income tax adjustments relate to adjusting our non-GAAP operating results to reflect an effective tax rate of 40% that would be applied if the Company was in a taxable income position and was not able to utilize its net operating loss carryforwards. The income tax adjustment also excludes any impact of a release of our valuation allowance against deferred tax assets.

13Earnings per share amounts for the three months and year ended December 31, 2012 do not add due to rounding.

Conference Call Details:

At 5:00 p.m. ET, February 26, 2013, Accelrys will conduct a conference call to discuss its financial results. To participate, please dial (866) 309-0459 (+ (937) 999-3232 outside the United States) and enter the access code, 88646167, approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible live on the Investor Relations section of the Accelrys website at www.accelrys.com.

A replay of the conference call will be available online at www.accelrys.com and via telephone by dialing (855) 859-2056 (+1 (404) 537-3406 outside the United States) and entering access code, 88646167, beginning 8:00 p.m. ET on February 26, 2013, through 11:59 p.m. ET on April 26, 2013.

About Accelrys:

Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad and flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

Accelrys solutions are used by more than 1,300 companies in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, California, USA, Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com.

Forward-Looking Statements:

Statements contained in this press release relating to the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future, including, but not limited to, statements relating to the Company's expected non-GAAP revenue and diluted earnings per share for the year ending December 31, 2013 and statements relating to the Company's long-term prospects and execution of its strategic growth and acquisition-related initiatives, are forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks that the Company will not achieve its expected non-GAAP revenue or diluted earnings per share for the year ending December 31, 2013 and/or that the Company will not successfully execute its strategic growth and acquisition-related initiatives, in each case due to, among other possibilities, an inability to withstand negative conditions in the global economy or a lack of demand for or market acceptance of the Company's products. Additional risks and uncertainties faced by the Company are contained from time to time in the Company's filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended December 31, 2011, quarterly reports on Form 10-Q and current reports on Form 8-K. Collectively, these risks and uncertainties could cause the Company's actual results to differ materially from those projected in its forward-looking statements, and the Company disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future events or otherwise.

ACCELRYS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(unaudited)

   
Three Months Ended Year Ended
December 31, December 31,
2012   2011 2012   2011
Revenue:
License and subscription revenue 23,149 $ 21,231 $ 89,440 $ 79,425
Maintenance on perpetual licenses 10,035 9,301 38,254 34,862
Content 2,991 4,270 12,485 16,838
Professional services and other 8,019   4,960   22,347   13,214  
Total revenue 44,194   39,762   162,526   144,339  
Cost of revenue:
Cost of revenue 11,961 9,501 41,695 36,065
Amortization of completed technology 2,580   2,135   8,843   8,393  
Total cost of revenue 14,541   11,636   50,538   44,458  
Gross profit 29,653 28,126 111,988 99,881
Operating expenses:
Product development 9,892 8,779 38,849 33,977
Sales and marketing 17,528 14,173 57,971 51,517
General and administrative 4,229 4,047 17,480 16,467
Business consolidation, transaction and restructuring costs 6,588 1,550 7,803 7,775
Purchased intangible asset amortization 2,619   2,503   8,939   9,846  
Total operating expenses 40,856   31,052   131,042   119,582  
Operating loss (11,203 ) (2,926 ) (19,054 ) (19,701 )
Net gain on sale of cost method investment 18,970 18,970
Royalty and other income, including gain on sale of real estate, net 1,763   (3,259 ) 8,870   1,740  
Income (loss) before income taxes (9,440 ) 12,785 (10,184 ) 1,009
Income tax expense (benefit) (1,211 ) (1,420 ) 218   (756 )
Net income (loss) $ (8,229 ) $ 14,205   $ (10,402 ) $ 1,765  
 
Net income (loss) per share amounts:
Basic $ (0.15 ) $ 0.26 $ (0.19 ) $ 0.03
Diluted $ (0.15 ) $ 0.25 $ (0.19 ) $ 0.03
Weighted average shares used to compute net income (loss) per share:
Basic 55,713 55,587 55,696 55,489
Diluted 55,713 55,933 55,696 56,037
 

ACCELRYS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

   

December 31,
2012

December 31,
2011

(unaudited) (audited)
Assets
Cash, cash equivalents, and marketable securities1 $ 115,646 $ 143,624
Trade receivables, net 47,196 40,706
Notes receivable 34,796 34,720
Other assets, net2 208,204   188,836
Total assets $ 405,842   $ 407,886
Liabilities and stockholders’ equity
Current liabilities, excluding deferred revenue 37,877 36,582
Deferred revenue, including current portion3 89,151 86,012
Deferred gain, including current portion4 25,895 25,974
Non-current liabilities, excluding deferred revenue and deferred gain5 10,098 10,634
Total stockholders’ equity 242,821   248,684
Total liabilities and stockholders’ equity $ 405,842   $ 407,886

1Cash, cash equivalents, and marketable securities consist of the following line items in our consolidated balance sheet: Cash and cash equivalents; Restricted cash; Marketable securities; Marketable securities, net of current portion; and Restricted cash, net of current portion.

2Other assets, net, consists of the following line items in our consolidated balance sheet: Prepaid expenses, deferred tax assets and other current assets; Property and equipment, net; Goodwill; Purchased intangible assets, net; and Other assets.

3Total deferred revenue consists of the following line items in our consolidated balance sheet: Current portion of deferred revenue; and Deferred revenue, net of current portion.

4Total deferred gain consists of the following line items in our consolidated balance sheet: Current portion of deferred gain on sale of intellectual property; and Deferred gain on sale of intellectual property, net of current portion.

5Noncurrent liabilities, excluding deferred revenue and deferred gain consists of the following line items in our consolidated balance sheet: Accrued income tax; Accrued restructuring charges, net of current portion and Lease-related liabilities, net of current portion.

About Business Wire
Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
You can then easily piece together full transaction traces by ordering all method calls by sequence number. Further analysis can be applied to this information for a number of purposes. For example, by analysing the transactions, developers can easily construct design diagrams that can...
Every day and every second, the system administrator gets tones of information on the network operation, network devices’ operation, and messages from users; he sets dozens of challenges, which must help to avoid the existing and possible problems in the future. Often, it is rather dif...
The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is ob...
With the increasing complexity of software, organizations are more cognizant than ever about the potential pitfalls of including open source code in their products. Below are some quick tips to continue leveraging open source code, while keeping your manager and legal department happy.
The industry is heated with debates on whether adopting private or public cloud is the smartest, best, cheapest, you name it choice. But this debate is missing the mark. Businesses shouldn’t be discussing public vs. private, but rather how can they make the two work together to their g...
In his session at 15th Cloud Expo, Mark Hinkle, Senior Director, Open Source Solutions at Citrix Systems Inc., will provide overview of the open source software that can be used to deploy and manage a cloud computing environment. He will include information on storage, networking(e.g.,...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE